dr. reddy’s Archives

LIC raises stake in Dr. Reddy’s

June 5, 2025June 5, 2025cpooldigitalLeave a Comment

In terms of number of shares, LIC had acquired more than 1.67 crore during this period, Dr. Reddy said in a filing. | Photo Credit: Reuters Life Insurance Corporation of India’s stake in Dr. Reddy’s Laboratories raced past the 8% mark recently with the country’s largest institutional investor acquiring an additional, more than 2% in […]

Dr Reddy’s gets two observations from USFDA for New York API plant

May 17, 2025May 17, 2025cpooldigitalLeave a Comment

Dr Reddy’s Laboratories on Saturday (May 17, 2025) said the U.S. health regulator has issued a Form 483 with two observations after inspecting its U.S.-based facility. The U.S. Food and Drug Administration completed a Good Manufacturing Practice (GMP) inspection at the company’s API (active pharmaceutical ingredients) Middleburgh facility in New York, Dr Reddy’s said in […]

Dr. Reddy’s acquiring Mayne Pharma’s U.S. generic portfolio for million

Dr. Reddy’s acquiring Mayne Pharma’s U.S. generic portfolio for $90 million

February 27, 2023February 27, 2023cpooldigitalLeave a Comment

Representational image only. | Photo Credit: Special Arrangement Pharma major Dr. Reddy’s Laboratories is acquiring the U.S. generic prescription product portfolio of Australia’s Mayne Pharma Group for an upfront cash consideration of around $90 million. The portfolio includes 45 commercial products, four pipeline products and 40 approved non-marketed products, including generic products focussed on women’s […]

Dr. Reddy’s completes Phase 1 study of proposed biosimilar of tocilizumab

December 19, 2022December 19, 2022cpooldigitalLeave a Comment

Dr. Reddy’s Laboratories shares gained on Monday in the backdrop of the drugmaker announcing successful completion of a phase-1 study of its proposed biosimilar of tocilizumab for use in the treatment of rheumatoid arthritis. DRL_TC, the biosimilar candidate, successfully met its primary and secondary endpoints in a Phase 1 study that used a subcutaneous formulation […]

Dr. Reddy’s faces anti-trust litigation in U.S. over cancer drug Revlimid

November 22, 2022November 23, 2022cpooldigitalLeave a Comment

A bottle of Revlimid and pills are seen at the Huntsman Cancer Institute at the University of Utah in Salt Lake City, Utah, U.S. File | Photo Credit: Reuters Dr. Reddy’s Laboratories and a few other drugmakers have been named defendants in a complaint filed in the U.S. under the Federal and State antitrust laws […]

Intercept Pharmaceuticals settles Ocaliva patent litigation case with Dr. Reddy’s

August 19, 2022August 19, 2022cpooldigitalLeave a Comment

For the full year 2021, Ocaliva net sales were $363.5 million including USA net sales of $260.8 million, which represented growth of 16% as compared to the prior year For the full year 2021, Ocaliva net sales were $363.5 million including USA net sales of $260.8 million, which represented growth of 16% as compared to […]

Dr. Reddy’s to acquire Slayback’s eyedrop rights

July 30, 2022July 30, 2022cpooldigitalLeave a Comment

Pharma major Dr. Reddy’s Laboratories has entered into a licensing agreement to obtain rights to New Jersey-based Slayback Pharma’s Brimonidine Tartrate Ophthalmic Solution 0.025%. Slayback Pharma is the first to file an ANDA (abbreviated new drug application) for the private label equivalent for Lumify with the U.S. Food and Drug Administration (USFDA) under Paragraph IV […]

Suboxone settlement boosts Dr. Reddy’s Q1 net

July 28, 2022July 28, 2022cpooldigitalLeave a Comment

Proceeds from a settlement pact with British drugmaker lndivior and its strategy of divesting brands to sharpen focus on core products aided pharma major Dr. Reddy’s Laboratories in reporting manifold increase in consolidated net profit to ₹1,189 crore for the first quarter. Besides contributing to the sharp rise from ₹380.4 crore of the year-earlier period, […]